Sarepta Therapeutics, Inc. (formerly AVI BioPharma, Inc.) — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012. The company was a development-stage biopharmaceutical focused on RNA-based therapeutics for rare and infectious diseases, including eteplirsen for Duchenne muscular dystrophy (DMD) and antiviral candidates for Ebola and Marburg.
Financial Results and Liquidity
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Revenue | $11.2 million | $14.3 million | Down 22% |
| Research and development expense | $14.8 million | $14.8 million | Approximately flat |
| General and administrative expense | $3.3 million | $5.0 million | Down 35% |
| Operating loss | $6.9 million | $5.5 million | Loss increased |
| Net income (loss) | $(17.7) million | $1.8 million | Declined by $19.5 million |
| Basic and diluted loss per share | $(0.13) | $0.02 | Unfavorable change |
| Cash used in operating activities | $9.0 million | $10.1 million | Use decreased |
| Cash and cash equivalents at period end | $30.6 million | $23.3 million | Prior-year comparative balance |
Revenue consisted almost entirely of U.S. government research contracts and grants and was recognized as related expenditures were incurred. The company had no material product-sales revenue. Gross margin was not meaningful because the filing presents government contract revenue and related expenses gross.
Cash and cash equivalents declined from $39.9 million at December 31, 2011 to $30.6 million at March 31, 2012. Total debt was approximately $1.8 million, including $86,000 current and $1.7 million non-current. Total current liabilities were $29.9 million, including a $16.4 million warrant liability. The company stated that available cash, excluding future government option funding, was sufficient to fund operations for at least the next 12 months.
Material Changes Versus Q1 2011
- Revenue decreased $3.1 million, primarily because the H1N1 contract ended in June 2011, eliminating $2.3 million of quarterly revenue, and because Ebola and Marburg contract revenue declined by $0.7 million.
- R&D spending remained level overall, as higher DMD spending of $1.8 million, primarily for the eteplirsen Phase IIb trial, was offset by lower H1N1, Ebola and Marburg, and personnel-related spending.
- G&A expense fell $1.7 million due mainly to lower personnel costs following the December 2011 reorganization and lower legal and professional fees.
- The company recorded a $10.9 million loss from the increase in the fair value of liability-classified warrants, compared with a $7.3 million gain in Q1 2011. The warrant liability increased from $5.4 million at year-end 2011 to $16.4 million at March 31, 2012, principally because of the higher stock price.
- The December 2011 restructuring, which reduced the workforce by 28%, was completed by January 31, 2012. Remaining severance accrual was $742,000 at March 31, 2012.
Guidance, Outlook, Risks and Unusual Items
- The company expected to release results from the eteplirsen open-label extension study in the fourth quarter of 2012 and intended to initiate a pivotal Phase III trial in 2013.
- In April 2012, the company reported that the 24-week, 30 mg/kg eteplirsen group met the Phase IIb primary efficacy endpoint, with a statistically significant increase in dystrophin-positive fibers. No significant clinical outcome improvement versus placebo was observed, and the filing noted that longer observation was needed.
- The July 2010 Ebola and Marburg agreement provided approximately $126.5 million of current-segment funding, of which $63.9 million had been recognized. If all government options were exercised, total potential funding could reach $288.0 million, including $161.5 million not yet funded. These options were discretionary and subject to appropriations and contract performance.
- The company had $3.3 million of deferred revenue and $2.6 million of unbilled U.S. government receivables at March 31, 2012.
- Management warned that government funding could be delayed, reduced or terminated for convenience or default. A loss of funding would likely require significant reductions in research and development spending and additional financing.
- The company expected continued operating losses and stated that it had never generated material commercial product revenue. Additional equity, equity-linked or debt financing, collaborations, or licensing transactions may be required, creating financing and dilution risk.
- Major development risks included clinical-trial failure or delay, uncertain dosing and efficacy for eteplirsen, regulatory uncertainty, use of the rarely applied Animal Rule for Ebola and Marburg, dependence on third-party manufacturers, intellectual-property disputes, and competition from other DMD and Ebola programs.
- As of the filing, the company was not party to material legal proceedings. Management reported effective disclosure controls and no material changes in internal control over financial reporting.
Investor Verification Checklist
- Verify the timing, design and results of the eteplirsen extension and subsequent Phase III program, including clinical outcomes beyond dystrophin expression.
- Confirm the status, appropriations and option exercise decisions associated with the Ebola and Marburg government contract.
- Reconcile cash burn and liquidity with the company’s stated 12-month funding outlook, excluding discretionary government options.
- Assess the valuation sensitivity and potential earnings volatility of the $16.4 million warrant liability.
- Review future financing needs, potential shareholder dilution, and the effects of outstanding warrants and options.
- Monitor regulatory, manufacturing and intellectual-property risks, including the Prosensa-related DMD patent dispute and the Animal Rule pathway.